The HTA review remains shrouded in secrecy, with brief and vaguely worded agendas released after meetings are held, no communiqués published for the past seven meetings, and organisations in other countries knowing more about the options under consideration and seeming to have more input than the Australian community.
But for a few selected insiders, the HTA review is a 'bin fire' of non-transparency
September 11, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 4 September
September 4, 2026 - - Podcast -
A three-pronged expansion of Commonwealth reach in therapeutic-goods regulation
September 4, 2026 - - Latest News -
If the government gives itself more power, don't be surprised when they use it
September 4, 2026 - - Latest News -
Medicines Australia calls for doubling of PBS medicines investment
September 4, 2026 - - Latest News -
Gilead returns to Medicines Australia as industry prepares to make the case for innovation
September 3, 2026 - - Latest News -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026 - - Latest News -
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 - - Latest News
